Press Releases

 
Press Releases
Date Title and Summary View
Mar 6, 2013 SALT LAKE CITY, March 6, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that three federal agencies including the U.S. Department of Health and Human Services, the U.S. Department of Labor, and the U.S. Department of the Treasury have issued a set of FAQs clarifying BRCA testing as a preventive service under the provis...
Mar 5, 2013 SALT LAKE CITY, March 5, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a study published in the Journal of Clinical Oncology demonstrated that its Prolaris test, which analyzes the expression level of 46 cell cycle progression genes, accurately predicted the elevated risk for prostate cancer recurrence in 413 men...
Mar 1, 2013 SALT LAKE CITY, March 1, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Noridian Administrative Services LLC ("Noridian"), Medicare administrative contractor for Jurisdiction F which includes Utah, has priced the new molecular pathology codes for calendar year 2013. Since all of Myriad's tests reimbursed by Medica...
Feb 5, 2013 SALT LAKE CITY, Feb. 5, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its second fiscal quarter ended December 31, 2012. Revenue for the second fiscal quarter increased 21 percent over the same period in the prior year to $149.1 million.  Second fiscal quarter earnings per diluted share were $0.42, an incr...
Jan 15, 2013 SALT LAKE CITY, Jan. 15, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the second fiscal quarter 2013 following the close of market on Tuesday, February 5, 2013. The Company will also host a conference call on Tuesday, February 5, 2013 at 4:30 P.M. Eastern to review the...
Dec 17, 2012 SALT LAKE CITY, Dec. 17, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the 2013 J.P. Morgan Annual Healthcare Conference, at 9:30 a.m. Pacific Time on Monday, January 7, 2013. The conference is being held at the Westin St. Francis in San Francisco, C...
Dec 10, 2012 SALT LAKE CITY, Dec. 10, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics (Nasdaq:MYGN) announced today that Myriad RBM, a wholly owned subsidiary of Myriad Genetics, has entered into a research collaboration with Sanofi, a global and diversified healthcare leader, and Population Health Research Institute (PHRI) at Hamilton Health Sciences and McMaster Uni...
Dec 7, 2012 SALT LAKE CITY, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled "Homologous recombination deficiency (HRD) score predicts pathologic response following neoadjuvant platinum-based therapy in triple-negative and BRCA1/2 mutation-associated breast cancer (BC)," was presented on Friday, ...
Nov 30, 2012 SALT LAKE CITY, Nov. 30, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) reported today that the Supreme Court of the United States granted certiorari agreeing to hear the case of The Association for Molecular Pathology, et al., v. Myriad Genetics, Inc., et al (Docket No. 12-398). The Supreme Court will review the earlier decision by t...
Nov 28, 2012 SALT LAKE CITY, Nov. 28, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled "CCP Score Significantly Predicts PSA Failure After EBRT," was presented on Wednesday, November 28th, 2012 at the Annual Meeting of the Society of Urological Oncology in Bethesda, Maryland. The study demonstrates that t...
Page: FirstPrevious ...
9
... NextLast
= add release to Briefcase